Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Chronic Idiopathic Urticaria Treatment Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The chronic idiopathic urticaria treatment market size has seen strong growth in recent years. It is projected to expand from $7.24 billion in 2025 to $7.89 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.0%. The growth observed in the historic period can be attributed to factors such as the increasing diagnosis of chronic urticaria, the availability of second-line antihistamine therapies, the adoption of stepwise treatment protocols, the expansion of allergy specialty clinics, and the growing use of immunomodulatory drugs.
The chronic idiopathic urticaria treatment market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $11.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.2%. This expected growth during the forecast period is driven by factors such as an increasing demand for biologic treatment options, a rising emphasis on personalized immunology care, the expansion of digital disease management tools, growing investments in novel urticaria therapies, and enhanced patient awareness alongside improved treatment adherence. Significant trends throughout this period include the increasing adoption of biologic therapies for refractory patients, the growing utilization of personalized treatment pathways, a rising integration of digital tools for symptom monitoring, the expansion of injectable treatment options, and an enhanced focus on long-term disease control.
Get A Free Sample Report With In-Depth Market Insights:
Chronic Idiopathic Urticaria Treatment Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The heightened attention on biologics is projected to drive expansion in the chronic idiopathic urticaria treatment market in the coming period. These biologics are therapeutic agents originating from living systems or their constituents, designed to precisely target immune system pathways for disease treatment. The increasing importance of biologics stems from progress in biotechnology and immunology, facilitating the creation of more accurate and potent therapies that address the fundamental mechanisms of immune-mediated conditions, instead of just alleviating symptoms. Biologics specifically target the foundational immune pathways and mast cell activation associated with chronic idiopathic urticaria, thus transforming treatment approaches and offering patients improved, enduring symptom management. As an illustration, in February 2025, the World Health Organization (WHO), an intergovernmental body based in Switzerland, reported that its 2023 Essential Medicines List features 81 biologic therapies, making up over 15% of all listed medications. Consequently, the growing emphasis on biologics is a key driver for the expansion of the chronic idiopathic urticaria treatment market.
Chronic Idiopathic Urticaria Treatment Market Segmentation And Category Overview
The chronic idiopathic urticaria treatment market covered in this report is segmented –
1) By Types: Tablets; Capsules; Creams; Lotions; Injections
2) By Drug Class: Antihistamines; Corticosteroids; Leukotriene Receptor Antagonists; Immunosuppressants; Biologic Therapies; Other Drug Class
3) By Route Of Administration: Oral; Injectable; Topical
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Tablets: Immediate Release Tablets; Extended Release Tablets; Enteric Coated Tablets; Chewable Tablets; Orally Disintegrating Tablets
2) By Capsules: Hard Gelatin Capsules; Soft Gelatin Capsules; Sustained Release Capsules; Delayed Release Capsules
3) By Creams: Medicated Topical Creams; Anti Inflammatory Creams; Antifungal Creams; Antibacterial Creams; Moisturizing Therapeutic Creams
4) By Lotions: Medicated Therapeutic Lotions; Anti Inflammatory Lotions; Antiseptic Lotions; Moisturizing Lotions; Specialty Dermatological Lotions
5) By Injections: Intravenous Injections; Intramuscular Injections; Subcutaneous Injections; Pre Filled Syringe Injections; Auto Injector Based Injections
Chronic Idiopathic Urticaria Treatment Market Innovation Trends Shaping Future Development
Leading companies in the chronic idiopathic urticaria treatment market are concentrating on the development of innovative products, such as monoclonal antibody therapies, to offer targeted, lasting relief for patients who do not respond to standard treatments. These monoclonal antibody therapies are biologic drugs specifically designed to target immune system components like immunoglobulin E (IgE) or other inflammatory mediators responsible for triggering chronic hives, providing a more precise action compared to traditional antihistamines or corticosteroids. For instance, in September 2025, Celltrion Inc., a South Korea-based biopharmaceutical company, introduced Omriclo, an omalizumab biosimilar, in Norway. This product consists of the same active monoclonal antibody as Xolair, operates by neutralizing circulating IgE, and is administered via subcutaneous injection. Its distinct features include a first-mover advantage in Europe, enhanced accessibility through local distribution channels, and potential cost savings for healthcare systems. It is intended for patients with chronic idiopathic urticaria who remain symptomatic despite standard therapy, offering a biologic alternative to conventional treatments, and aiming to provide improved symptom management, reduced frequency of flare-ups, and the potential to enhance overall quality of life by minimizing reliance on long-term antihistamine or corticosteroid use.
Chronic Idiopathic Urticaria Treatment Market Key Participants And Competitive Landscape
Major companies operating in the chronic idiopathic urticaria treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG., AstraZeneca PLC, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Celltrion Inc., Yuhan Corporation, Kiniksa Pharmaceuticals Ltd., Celldex Therapeutics Inc., Septerna Therapeutics Inc., Carna Biosciences Inc., United BioPharma Inc., Recludix Pharma Inc., Jasper Therapeutics Inc., Evommune Inc., ARS Pharmaceuticals Inc
View The Full Chronic Idiopathic Urticaria Treatment Market Report:
Chronic Idiopathic Urticaria Treatment Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the chronic idiopathic urticaria treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic idiopathic urticaria treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model